Synthetic PPARγ ligands, several ofwhich are currently approved for treatment of diabetes, can interrupt severalstages of the COX-2/PGE2 protumorigenic pathway, although in certaincases PPARγ ligands may increase COX-2 expression. The gene discussed is PTGS2; the disease is diabetes mellitus.